MHC and KIR Sequencing and Association Analyses in the iGeneTRAiN Studies

项目摘要 HLA供受体（D-R）配型对肾、心、肺移植后的移植结局至关重要 和造血细胞移植。在大规模特征良好的 缺乏移植队列，明确需要描述MHC和KIR如何影响移植的结果。 遗传变异是移植结果的基础。国际遗传学和翻译 移植研究网络（iGeneTRAiN）的成立是为了增加对 移植结果的遗传结构， 全基因组关联研究（GWAS）数据集来自超过52，600名受体/供体， 精心策划的心脏、肾脏、肝脏和肺移植表型数据集。这构成了 最大的实体器官移植联盟战略制药合作 我们在大多数iGeneTRAiN研究中对关键的HLA I类和II类进行测序， 在研究的子集中，额外的MHC/KIR区域，促进了充足的统计能力， 评估HLA和KIR与关键移植相关结局的关联研究。大 iGeneTRAiN数据库的一部分来自非欧洲血统样本， 大大解决了这些人群中缺乏足够的MHC/KIR遗传数据的问题。

PROJECT SUMMARY HLA donor-recipient (D-R) matching is critical for graft outcomes following Kidney, Heart, Lung and hematopoietic cell transplantation. Genetic association studies in large well-characterized transplant cohorts are lacking and there is a clear need to characterize how MHC and KIR genetic variants underpin transplantation outcomes. The International Genetics & Translational Research in Transplantation Network (iGeneTRAiN) was formed to increase the understanding of the genetic architecture of transplant outcomes, by bringing together transplantation studies with genome-wide association study (GWAS) datasets from >52,600 recipients/donors across well-curated heart, kidney, liver and lung transplant phenotype datasets. This constitutes the largest solid-organ transplant consortium ever assembled. A strategic Pharma collaboration where we sequence key HLA Class I and II in the majority of iGeneTRAiN studies, and additional MHC/KIR regions in subsets of studies, is facilitating ample statistical power to assess association studies of HLA and KIR with key transplant-related outcomes. A large portion of the iGeneTRAiN database is derived from non-European ancestry samples, which greatly addresses the lack of adequate MHC/KIR genetic data in these populations.